Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.
Nat Microbiol
; 5(10): 1185-1191, 2020 10.
Article
in English
| MEDLINE | ID: covidwho-752497
ABSTRACT
Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Viral Vaccines
/
Coronavirus Infections
/
Antibody-Dependent Enhancement
/
Betacoronavirus
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Nat Microbiol
Year:
2020
Document Type:
Article
Affiliation country:
S41564-020-00789-5
Similar
MEDLINE
...
LILACS
LIS